Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Sees Significant Decrease in Short Interest

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was the target of a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 173,306 shares, a decrease of 34.0% from the July 30th total of 262,477 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily trading volume, of 271,752 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TVRD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a report on Wednesday, July 8th. HC Wainwright assumed coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price target on the stock. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. Finally, Wall Street Zen cut Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tvardi Therapeutics Stock Down 1.3%

Shares of Tvardi Therapeutics stock traded down $0.02 during trading on Tuesday, reaching $1.78. 23,678 shares of the company were exchanged, compared to its average volume of 917,303. The business has a 50-day moving average price of $2.30 and a 200-day moving average price of $3.02. The firm has a market capitalization of $23.69 million, a price-to-earnings ratio of -0.64 and a beta of 0.39. Tvardi Therapeutics has a twelve month low of $1.50 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, equities research analysts forecast that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the second quarter valued at approximately $43,000. HRT Financial LP acquired a new stake in shares of Tvardi Therapeutics in the fourth quarter valued at approximately $47,000. XTX Topco Ltd bought a new position in shares of Tvardi Therapeutics during the 4th quarter worth approximately $55,000. Russell Investments Group Ltd. boosted its stake in shares of Tvardi Therapeutics by 1,351.5% during the 4th quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock worth $69,000 after acquiring an additional 14,866 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $80,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.